Filing Flows › 10x Genomics (TXG) › Capital expenditures
10x Genomics (TXG) capital expenditures by quarter
10x Genomics' capital expenditures were $971K in Q3 2026 (third quarter 2026), -39% from Q2 2026. Over the last 7 quarters it ranged from $687K (Q3 2025) to $1.9M (Q1 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $971K | -39% | +41% |
| Q2 2026 | $1.6M | -0.6% | +0.6% |
| Q1 2026 | $1.6M | -10% | -16% |
| Q4 2025 | $1.8M | +159% | — |
| Q3 2025 | $687K | -56% | — |
| Q2 2025 | $1.6M | -17% | — |
| Q1 2025 | $1.9M | — | — |
Q3 2026 at a glance
10x Genomics, Q3 2026: revenue $151M (+1% year over year), operating margin -10.7%, net loss $19.4M, operating cash flow $15.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is 10x Genomics' capital expenditures?
10x Genomics' capital expenditures were $971K in Q3 2026 (third quarter 2026), -39% from Q2 2026.
How has 10x Genomics' capital expenditures changed?
Over the last 7 quarters it ranged from $687K (Q3 2025) to $1.9M (Q1 2025).